BioLife Solutions Inc (BLFS) VP Todd Berard Sells 3,000 Shares

BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $16.96, for a total value of $50,880.00. Following the transaction, the vice president now directly owns 44,074 shares in the company, valued at approximately $747,495.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Todd Berard also recently made the following trade(s):

  • On Monday, April 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.56, for a total value of $52,680.00.
  • On Thursday, March 14th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The shares were sold at an average price of $16.67, for a total value of $50,010.00.

NASDAQ:BLFS traded up $0.48 on Friday, hitting $18.22. 129,500 shares of the company’s stock traded hands, compared to its average volume of 159,005. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99. BioLife Solutions Inc has a 1 year low of $8.50 and a 1 year high of $26.35. The stock has a market cap of $336.52 million, a PE ratio of 130.14 and a beta of 1.53.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.03. The company had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. On average, equities research analysts anticipate that BioLife Solutions Inc will post 0.13 earnings per share for the current year.

Several equities analysts have weighed in on the company. BidaskClub cut BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Zacks Investment Research raised BioLife Solutions from a “sell” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Wednesday. ValuEngine cut BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 27th. Finally, Northland Securities reaffirmed a “buy” rating and set a $18.00 target price on shares of BioLife Solutions in a research note on Monday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $18.20.

Several institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its holdings in shares of BioLife Solutions by 2.9% during the 1st quarter. Janney Montgomery Scott LLC now owns 21,115 shares of the medical equipment provider’s stock valued at $378,000 after buying an additional 600 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of BioLife Solutions by 21.1% during the 4th quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 2,400 shares during the last quarter. Cadence Capital Management LLC lifted its holdings in shares of BioLife Solutions by 1.8% during the 1st quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock valued at $3,493,000 after buying an additional 3,439 shares during the last quarter. Cowen Prime Services LLC acquired a new stake in shares of BioLife Solutions during the 1st quarter valued at about $63,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of BioLife Solutions by 4.2% during the 1st quarter. Wells Fargo & Company MN now owns 93,146 shares of the medical equipment provider’s stock valued at $1,667,000 after buying an additional 3,784 shares during the last quarter. Institutional investors and hedge funds own 41.21% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thelincolnianonline.com/2019/05/17/biolife-solutions-inc-blfs-vp-todd-berard-sells-3000-shares-3.html.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: Growth Stocks, What They Are, What They Are Not

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.